Puracap Laboratories LLC

Exeltis USA Inc, based in Florham Park, NJ, is a leading provider of women's health products, dedicated to empowering women to lead their healthiest lives. With a commitment to delivering extraordinary solutions for evolving women's health needs, Exeltis collaborates and innovates to meet emerging healthcare challenges and provide unique formulations that support women at every stage of life. Driven by a vision of excellence, Exeltis is fearless in its pursuit of better health options for patients. The company not only offers exceptional products but also fosters professional development opportunities for healthcare professionals, while fulfilling social responsibilities through its partnership with the Mundo Sano non-profit foundation. With a focus on collaboration, innovation, and social impact, Exeltis is at the forefront of women's health expertise.Generated from the website

Gemini Laboratories, a subsidiary of Amneal Pharmaceuticals based in Bridgewater, NJ, is committed to creating essential medicines and advancing healthcare through a diverse portfolio of approximately 280 generic and specialty pharmaceuticals. The company prioritizes innovation and accessibility, developing first-to-file and first-to-market complex medicines while supporting patients and communities in navigating conditions such as Parkinson's disease. With a strong focus on patient care, Gemini Laboratories actively contributes to public health initiatives, including increasing access to critical medications like Naloxone Nasal Spray. Their culture emphasizes collaboration and dedication, driving efforts to make healthy possible for patients and their families. Generated from the website

SIGA Technologies applies microbial genomics to the design and development of novel products that prevent and treat infectious diseases, as well as defend against biological warfare agents. With technology platforms in both vaccines and antibiotics, the company s platform technologies include a vaccine delivery system that activates the immune system at the body s mucosal surfaces in order to prevent infection at the earliest possible stage, a surface protein expression system for the cost-effective production of proteins, biothreat rapid response therapeutics that can be rapidly designed on demand for any biological pathogen and virus counterstrike capability technology that can be used to develop safe and effective antivirals by targeting the proteinases which are encoded within all viruses. SIGA Technologies is headquartered in New York.